Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Common Equity: 2020-2024

Historic Common Equity for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $228.5 million.

  • Apellis Pharmaceuticals' Common Equity rose 69.18% to $401.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.2 million, marking a year-over-year increase of 69.18%. This contributed to the annual value of $228.5 million for FY2024, which is 17.49% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Common Equity is $228.5 million, which was up 17.49% from $194.5 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Common Equity high stood at $228.5 million for FY2024, and its period low was $169.9 million during FY2022.
  • Moreover, its 3-year median value for Common Equity was $194.5 million (2023), whereas its average is $197.6 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Common Equity dropped by 14.49% in 2022, and later climbed by 17.49% in 2024.
  • Apellis Pharmaceuticals' Common Equity (Yearly) stood at $204.6 million in 2020, then dropped by 2.88% to $198.7 million in 2021, then decreased by 14.49% to $169.9 million in 2022, then rose by 14.51% to $194.5 million in 2023, then increased by 17.49% to $228.5 million in 2024.